FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 14:27:06 2024-05-31 EDT | ||
| 1.025 EUR | +18.91% |
|
| 1 month | +140.05% | ||
| 3 months | +6.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 1.025 | +18.91% |
| 24-05-30 | 0.862 | -6.30% |
| 24-05-29 | 0.92 | -8.91% |
| 24-05-28 | 1.01 | -20.47% |
| 24-05-27 | 1.27 | +6.72% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 02:27 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GK3GNH |
| ISIN | DE000GK3GNH8 |
| Date issued | 2022-04-14 |
| Strike | 387.7 $ |
| Maturity | Unlimited |
| Parity | 57.09 : 1 |
| Emission price | 10.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.88 € |
|---|---|
| Lowest since issue | 0.364 € |
| Spread | 0.03 € |
| Spread % | 2.63% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
